NASDAQ$ARWR
Arrowhead Pharmaceuticals Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Arrowhead Pharmaceuticals reported fiscal year end results.
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2020. The company earned two $20 million milestone payments from Amgen and signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT.
- Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890.
- Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis.
- Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma.
- Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront.
Headline financials
Revenue & EPS history
Arrowhead Pharmaceuticals · Revenue · Quarterly
$7.63M
Forward guidance
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Tailwinds
- Broad portfolio of RNA chemistries
- Efficient modes of delivery
- Therapies trigger the RNA interference mechanism
- Rapid knockdown of target genes
- Durable knockdown of target genes
Headwinds
- Safety and efficacy of product candidates
- Duration and impact of regulatory delays in clinical programs
- Ability to finance operations
- Likelihood and timing of the receipt of future milestone and licensing fees
- Future success of scientific studies
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+0.0%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+10.8%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+39.2%
Q4 2024
Best reaction
-26.7%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.6% | +0.1% | -6.1% | |
| Q1 2026 | -0.2% | -4.8% | -7.5% | |
| Q4 2025 | +23.2% | +20.2% | +49.9% | |
| Q2 2025 | +9.4% | +12.5% | +16.1% | |
| Q1 2025 | -5.2% | +0.2% | -24.3% | |
| Q4 2024 | +39.2% | +38.5% | +3.9% | |
| Q3 2024 | -6.4% | -8.6% | -11.1% | |
| Q2 2024 | -12.5% | -9.2% | -5.2% | |
| Q1 2024 | -1.2% | +1.7% | +3.7% | |
| Q4 2023 | -26.7% | -13.8% | +5.8% | |
| Q3 2023 | -13.1% | -8.8% | -7.7% | |
| Q2 2023 | +12.5% | +15.8% | -2.9% | |
| Q1 2023 | -8.5% | -9.9% | -19.3% | |
| Q4 2022 | +1.7% | +15.0% | +27.3% | |
| Q3 2022 | +3.6% | +2.5% | -11.1% | |
| Q2 2022 | -11.5% | -3.3% | -0.7% | |
| Q1 2022 | -11.1% | -5.4% | -22.1% | |
| Q4 2021 | -0.3% | +1.3% | -1.8% | |
| Q3 2021 | -2.0% | -7.4% | +2.2% | |
| Q2 2021 | -5.4% | -5.5% | +3.2% | |
| Q1 2021 | +12.6% | +11.8% | -14.1% | |
| Q4 2020 | -12.2% | -8.4% | +24.1% | |
| Q3 2020 | -7.0% | -8.5% | -18.3% | |
| Q2 2020 | -0.3% | +5.0% | -0.5% | |
| Q1 2020 | -6.4% | -2.4% | -23.9% | |
| Q4 2019 | +37.6% | +48.4% | +31.2% | |
| Q3 2019 | -2.1% | -0.2% | +17.6% | |
| Q2 2019 | +8.0% | +0.1% | +50.2% | |
| Q1 2019 | +13.2% | +25.4% | +33.0% | |
| Q4 2018 | +11.2% | +4.8% | +9.8% | |
| Q3 2018 | +13.2% | +18.6% | +36.2% | |
| Q2 2018 | +15.8% | +27.2% | +33.5% | |
| Q1 2018 | -6.2% | -3.4% | +30.9% | |
| Q4 2017 | -3.1% | -10.5% | +43.6% | |
| Q3 2017 | +8.9% | +13.6% | +69.2% | |
| Q2 2017 | +13.5% | +6.4% | +3.8% | |
| Q1 2017 | +3.2% | +3.7% | +12.1% | |
| Q4 2016 | +0.0% | -1.6% | +62.2% | |
| Q3 2016 | -1.2% | +1.0% | +29.7% | |
| Q2 2016 | -3.1% | — | — | |
| Q1 2016 | -0.9% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | +12.1% | — | — | |
| Q2 2015 | -10.9% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -10.7% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | +2.5% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -7.2% | — | — | |
| Q3 2012 | -16.8% | — | — | |
| Q2 2012 | -4.5% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | +0.5% | — | — | |
| Q2 2011 | +0.5% | — | — | |
| Q3 2011 | -12.4% | — | — | |
| Q3 2010 | -12.4% | — | — | |
| Q4 2010 | -12.4% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q2 2010 | -8.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro